Trademark Overview
On Wednesday, November 6, 2024, a trademark application was filed for CATALYTAC with the United States Patent and Trademark Office. The USPTO has given the CATALYTAC trademark a serial number of 98840485. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Saturday, May 24, 2025. This trademark is owned by Lycia Therapeutics, Inc.. The CATALYTAC trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceutical preparations comprising small molecules and antibodies for degrading disease-causing cellular proteins for treatment of cancer, autoimmune diseases, immunologic-based diseases, neurological diseases, and other human diseases; Pharmaceutical preparations for the prevention and treatment of cancer, autoimmune diseases, immunologic-based diseases, neurological diseases, and other human diseases; Biological preparations for the prevention and treatment of cancer, autoimmune diseases, immunologic-based diseases, neurological diseases, and other human diseases; Gene therapy products, namely, biological preparations for the treatment of cancer, autoimmune diseases, immunologic-based diseases, neurological diseases, and other human diseases; Pharmaceutical preparations for use in gene therapy; Biological preparations for use in gene therapy; Viruses for therapeutic purposes, namely, for gene therapy and antivirals
Providing medical information; Providing medical information via a website; Medical services; Medical diagnostic testing, medical clinics, medical screenings, medical examinations and medical treatment services; Provision of pharmaceutical information; Pharmaceutical services, consultations and advice
Research and development services in the field of pharmaceuticals; drug discovery services
